ILF3 and neoplasm: The results revealed that the statin-treated group (Fig. 2A) and the low-ILF3 (Fig. 2B) and low-PD-L1 (Fig. 2C) expression groups exhibited more prominent tumor regression and were more sensitive to neoadjuvant chemotherapy on the basis of TRG grading.